Table 2.
Malignancy Characteristics, by Participant
| ID | Type of NSCLC | Stage | Chemotherapy | Location of Obstruction | Device Used to Recannulate |
|---|---|---|---|---|---|
| 1 | Adenocarcinoma | 4 | Pemetrexed, carboplatin | RUL | Forceps |
| 2 | Squamous cell carcinoma | 3A | Paclitaxel | RMS | Forceps, argon plasma coagulation |
| 3 | Squamous cell carcinoma | 2B | Paclitaxel | RMS | Forceps, argon plasma coagulation |
| 4 | Squamous cell carcinoma | 4 | Cisplatin, etoposide | LUL | Forceps |
| 5 | Adenocarcinoma | 4 | Pemetrexed, carboplatin | RUL | Forceps, argon plasma coagulation |
| 6 | Adenocarcinoma | 3C | Pemetrexed, carboplatin, bevacizumab | RML | Forceps |
| 7 | Adenocarcinoma | 3B | Cisplatin | RUL | Forceps |
| 8 | Adenocarcinoma | 4 | Docetaxel | BI | Forceps |
| 9 | Adenocarcinoma | 1B | None | BI | Forceps |
| 10 | Adenocarcinoma | 4 | Erlotinib | RML | Forceps |
| 11 | Adenocarcinoma | 4 | Pemetrexed, carboplatin | RUL | Forceps |
| 12 | Squamous cell carcinoma | 4 | Paclitaxel, carboplatin | LUL | Forceps |
| 13 | Squamous cell carcinoma | 3A | Paclitaxel, carboplatin | BI | Forceps, argon plasma coagulation |
| 15 | Squamous cell carcinoma | 3B | None | RLL | Forceps |
| 17 | Squamous cell carcinoma | 4 | Carboplatin, paclitaxel | RML | Forceps |
| 19 | Adenocarcinoma | 3A | Cisplatin | RMS | Electrocautery, cryotherapy, forceps |
| 20 | Squamous cell carcinoma | 3A | Erlotinib | RMS | Forceps |
| 21 | Adenosquamous | 4 | Carboplatin, paclitaxel | LMB | Forceps |
| 22 | Squamous cell carcinoma | 3B | Nivolumab | LMB | Forceps |
| 23 | Squamous cell carcinoma | 2B | None | LMB | Forceps, argon plasma coagulation |
BI = bronchus intermedius; LMB = left mainstem bronchus; LUL = left upper lobe; RLL = right lower lobe; RML = right middle lobe; RMS = right mainstem bronchus; RUL = right upper lobe. See Table 1 legend for expansion of other abbreviation.